SEOUL, Nov. 29 (Korea Bizwire) — The ruling Democratic Party has raised its coronavirus vaccine supply target to 44 million people, or 85 percent of the country’s population, a key party source said Sunday. The figure is sharply higher than the 30 million target previously cited by health authorities. To secure the vaccines, the party [...]
SEOUL, Nov. 25 (Korea Bizwire) — South Korea joined the Coalition for Epidemic Preparedness Initiative (CEPI) and pledged to donate US$3 million this year to help develop vaccines for COVID-19 and other emerging epidemics, the foreign ministry said Wednesday. The CEPI is a global partnership joined by public, private and civil society organizations to fund [...]
SEOUL, Nov. 24 (Korea Bizwire) – South Korea’s drug safety agency has approved clinical trials of vaccine and treatment candidates currently under development by two local drug manufacturers, industry officials said Tuesday. The Ministry of Food and Drug Safety on Monday gave the green light to conduct a phase one clinical trial of a vaccine [...]
STUART, Fla., Nov. 18 (Korea Bizwire) – The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that in anticipation of COVID-19 vaccines becoming available soon, the Company has procured factory capacity for production of over one billion, FDA-approved hypodermic needles and syringes that will be required for administration [...]
SEOUL, Nov. 18 (Korea Bizwire) — A number of major South Korean pharmaceutical companies have recently signed a series of deals to manufacture vaccines and treatment drugs for the novel coronavirus, industry watchers said Wednesday. Among the front-runners is industry leader Samsung Biologics Co., which successfully inked two contract manufacturing organization (CMO) agreements this year. [...]
SEOUL, Nov. 13 (Korea Bizwire) — South Korean bio company GL Rapha will produce over 150 million annual doses of Russia’s COVID-19 vaccine for global distribution, Russia’s sovereign wealth fund said Friday. The Russian Direct Investment Fund (RDIF) said GL Rapha will begin manufacturing Sputnik V in South Korea next month, which it described “the [...]
GAITHERSBURG, Md., Nov. 9 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made [...]
GAITHERSBURG, Md., Nov. 4 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding Heads of Terms document with the Australian Government to supply 40 million doses of the Company’s COVID-19 vaccine candidate, NVX-CoV2373, for the Australian community. “This [...]
WASHINGTON, Oct. 28 (Korea Bizwire) — The Sabin Vaccine Institute (Sabin) today announced that it has partnered with Dalberg and JSI Research & Training Institute, Inc. (JSI) to create the COVID-19 Vaccine Equity Project (vaccineequity.org). This collaboration will support low- and middle-income country immunization professionals in leading the equitable delivery of COVID-19 vaccines through their national immunization programs [...]
GAITHERSBURG, Md., Oct. 27 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. The Company [...]